Duration of Adjuvant Chemotherapy for Stage III Colon Cancer | Zendy

Axel Grothey | Zendy; Alberto Sobrero | Zendy; Anthony F. Shields | Zendy; Takayuki Yoshino | Zendy; James Paul | Zendy; Julien Taı̈eb | Zendy; John Souglakos | Zendy; Qian Shi | Zendy; Rachel Kerr | Zendy; Roberto Labianca | Zendy; Jeffrey A. Meyerhardt | Zendy; Déwi Vernerey | Zendy; Takeharu Yamanaka | Zendy; Ioannis Boukovinas | Zendy; Jeffrey P. Meyers | Zendy; Lindsay A. Renfro | Zendy; Doniedzwiecki | Zendy; Toshiaki Watanabe | Zendy; Valter Torri | Zendy; Mark Saunders | Zendy; Daniel J. Sargent | Zendy; Thierry André | Zendy; Timothy Iveson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Author(s) -

Axel Grothey,

Alberto Sobrero,

Anthony F. Shields,

Takayuki Yoshino,

James Paul,

Julien Taı̈eb,

John Souglakos,

Qian Shi,

Rachel Kerr,

Roberto Labianca,

Jeffrey A. Meyerhardt,

Déwi Vernerey,

Takeharu Yamanaka,

Ioannis Boukovinas,

Jeffrey P. Meyers,

Lindsay A. Renfro,

Doniedzwiecki,

Toshiaki Watanabe,

Valter Torri,

Mark Saunders,

Daniel J. Sargent,

Thierry André,

Timothy Iveson

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1713709

Subject(s) - oxaliplatin , medicine , regimen , colorectal cancer , stage (stratigraphy) , adjuvant , oncology , duration (music) , adjuvant chemotherapy , adjuvant therapy , chemotherapy , cancer , art , paleontology , literature , breast cancer , biology

Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research